SIMCERE PHARMA's Novel Stroke Treatment Included in National Essential Medicines List

Stock News

Jul 09

An announcement has been made by SIMCERE PHARMA (02096) regarding a significant development for its flagship product.

The company's self-developed Class 1 innovative drug, Xianbixin® (edaravone dexborneol concentrated solution for injection), has been officially included in the National Essential Medicines List (2026 edition) as of July 9, 2026. The drug is indicated for the treatment of acute ischemic stroke (AIS).

In accordance with regulations governing essential medicines, all public medical institutions across the country are required to stock and prioritize the use of drugs listed in this directory.

This inclusion is expected to enable Xianbixin® to expand beyond its current primary focus on top-tier hospitals. It will accelerate the drug's penetration into county-level and primary healthcare markets, broadening its prescription scenarios at the point of care.

Combined with its existing coverage under national medical insurance schemes, this move is anticipated to significantly enhance the drug's accessibility. It will further solidify the company's competitive advantage in the field of acute stroke treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1142792573"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142792573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142792573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142792573","market":"hk","top_or_hot":-1,"title":"SIMCERE PHARMA's Novel Stroke Treatment Included in National Essential Medicines List","media":"Stock News","content":"<p>An announcement has been made by <b>SIMCERE PHARMA</b> (<b>02096</b>) regarding a significant development for its flagship product.<br><br>The company's self-developed Class 1 innovative drug, Xianbixin® (edaravone dexborneol concentrated solution for injection), has been officially included in the National Essential Medicines List (2026 edition) as of July 9, 2026. The drug is indicated for the treatment of acute ischemic stroke (AIS).<br><br>In accordance with regulations governing essential medicines, all public medical institutions across the country are required to stock and prioritize the use of drugs listed in this directory.<br><br>This inclusion is expected to enable Xianbixin® to expand beyond its current primary focus on top-tier hospitals. It will accelerate the drug's penetration into county-level and primary healthcare markets, broadening its prescription scenarios at the point of care.<br><br>Combined with its existing coverage under national medical insurance schemes, this move is anticipated to significantly enhance the drug's accessibility. It will further solidify the company's competitive advantage in the field of acute stroke treatment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA's Novel Stroke Treatment Included in National Essential Medicines List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA's Novel Stroke Treatment Included in National Essential Medicines List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-09 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An announcement has been made by <b>SIMCERE PHARMA</b> (<b>02096</b>) regarding a significant development for its flagship product.<br><br>The company's self-developed Class 1 innovative drug, Xianbixin® (edaravone dexborneol concentrated solution for injection), has been officially included in the National Essential Medicines List (2026 edition) as of July 9, 2026. The drug is indicated for the treatment of acute ischemic stroke (AIS).<br><br>In accordance with regulations governing essential medicines, all public medical institutions across the country are required to stock and prioritize the use of drugs listed in this directory.<br><br>This inclusion is expected to enable Xianbixin® to expand beyond its current primary focus on top-tier hospitals. It will accelerate the drug's penetration into county-level and primary healthcare markets, broadening its prescription scenarios at the point of care.<br><br>Combined with its existing coverage under national medical insurance schemes, this move is anticipated to significantly enhance the drug's accessibility. It will further solidify the company's competitive advantage in the field of acute stroke treatment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1142792573","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142792573","pubTimestamp":1783598898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An announcement has been made by SIMCERE PHARMA (02096) regarding a significant development for its flagship product.The company's self-developed Class 1 innovative drug, Xianbixin® (edaravone...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","02096":"先声药业"},"translate_title":"先声药业脑卒中治疗新药纳入国家基本药物目录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"An announcement has been made by SIMCERE PHARMA (02096) regarding a significant development for its flagship product.The company's self-developed Class 1 innovative drug, Xianbixin® (edaravone dexborneol concentrated solution for injection), has been officially included in the National Essential Medicines List (2026 edition) as of July 9, 2026. The drug is indicated for the treatment of acute ischemic stroke (AIS).In accordance with regulations governing essential medicines, all public medical institutions across the country are required to stock and prioritize the use of drugs listed in this directory.This inclusion is expected to enable Xianbixin® to expand beyond its current primary focus on top-tier hospitals. It will accelerate the drug's penetration into county-level and primary healthcare markets, broadening its prescription scenarios at the point of care.Combined with its existing coverage under national medical insurance schemes, this move is anticipated to significantly enhance the drug's accessibility. It will further solidify the company's competitive advantage in the field of acute stroke treatment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}